MedTrace Logo

Hyperglycemia in Surgical Infections

NCT00353275 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-11-21

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate two glycemic control regimens on clinical outcome in patients with necrotizing soft tissue infections. Secondary aim is to evaluate the inflammatory and immune responses to the glycemic control regimens.

Conditions

  • Necrotizing Fasciitis

Interventions

DRUG

Strict Glycemic control

Blood glucose target range is 80-110 mg/dL.

DRUG

Conventional Glycemic Control

Blood glucose target range is 110-140 mg/dL.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Lillian S Kao, MD · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353275 on ClinicalTrials.gov